High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib

J.L. Kuiper, D.A.M. Heideman, E. Thunnissen, A.W. van Wijk, P.E. Postmus, E.F. Smit

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Scopus)
Original languageEnglish
Pages (from-to)1399-401
Number of pages3
JournalEuropean Journal of Cancer
Issue number7
Publication statusPublished - May 2014


  • Antineoplastic Agents/administration & dosage
  • Carcinoma, Non-Small-Cell Lung/drug therapy
  • Disease Progression
  • ErbB Receptors/genetics
  • Erlotinib Hydrochloride
  • Humans
  • Lung Neoplasms/drug therapy
  • Meningeal Neoplasms/drug therapy
  • Protein Kinase Inhibitors/administration & dosage
  • Quinazolines/administration & dosage

Cite this